The sFlt-1/PlGF Ratio in Pregnant Patients Affected by COVID-19

Kosińska-Kaczyńska, Katarzyna; Malicka, Ewa; Szymusik, Iwona; Dera, Norbert; Pruc, Michał; Feduniw, Stepan; Rafique, Zubaid; Szarpak, Łukasz

doi:10.3390/jcm12031059

Cited by 9 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meta-analysis conducted by Kosińska-Kaczyńska et al included of 7 studies, revealed that sFlt-1/PlGF ratios between COVID-19 positive vs. negative women were higher, 45.8 ± 50.3 vs. 37.4 ± 22.5, respectively (SMD = 1.76; 95% CI: 0.43 to 3.09; p = 0.01) [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

sFlT-1/PlGF ratio as a predictor of preeclampsia in COVID-19 pregnant patients

Pluta,

Januszewski,

Ziuzia-Januszewska

et al. 2024

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

The association between SARS-CoV-2 infection in pregnancy and preeclampsia is widely debated in numerous studies. The aim of our study was to investigate whether an increased sFlt-1/PlGF ratio is a good marker of preeclampsia in pregnant patients with COVID-19 infection. This single centre prospective study was conducted in the Department of Obstetrics and Gynaecology, at the Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw. The study group consisted of 68 COVID-19 pregnant patients and 57 SARS-CoV-2 negative pregnant controls. Serum sFlt-1/PlGF ratio was assessed. The two groups did not differ in terms of the frequency of IVF, nulliparity, history of hypertension, pre-gestational diabetes and chronic kidney disease. The primary outcome was the diagnosis of preeclampsia. Preeclampsia was diagnosed in 10 patients in both groups. The sFlt-1/PlGF ratio higher than 38, considered highly suggestive of developing preeclampsia, was found in 20 patients in the COVID-19 group and 15 patients in the control group. The odds of developing preeclampsia in patients with sFlt-1/PlGF ratio > 38 was approximately 4-fold higher in COVID-19 group and 11-fold higher in controls. Sflt-1/PlGF ratio does not differ significantly between the SARS-CoV-2-positive and SARS-COV-2-negative pregnant patients. The sFlt-1/PlGF ratio > 38 is associated with higher odds of the diagnosis of preeclampsia in both of these groups, and therefore may serve as its marker regardless of COVID-19 infection status.

show abstract

Section: Discussionmentioning

confidence: 99%

sFlT-1/PlGF ratio as a predictor of preeclampsia in COVID-19 pregnant patients

Pluta,

Januszewski,

Ziuzia-Januszewska

et al. 2024

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

show abstract

“…SARS-CoV-2 affects the secretion of cytokines and growth factors [ 47 ]. The importance of biomarkers in diagnosing PE is becoming recognized.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 Infection and Preeclampsia—How an Infection Can Help Us to Know More about an Obstetric Condition

Vanegas

Pérez

2023

Viruses

View full text Add to dashboard Cite

Pregnant women with SARS-CoV-2 infection have a significantly higher risk of maternal death, ICU admission, preterm delivery, and stillbirth compared to those without infection. Additionally, the risk of preeclampsia (PE) increases in pregnant women infected with SARS-CoV-2, particularly in severe cases. The association between COVID-19 and PE is likely attributed to various mechanisms, including direct effects of the virus on trophoblast function and the arterial wall, exaggerated inflammatory response in pregnant women, local inflammation leading to placental ischemia, SARS-CoV-2-related myocardial injury, cytokine storm, and thrombotic microangiopathy. This paper aims to explore the similarities between PE and SARS-CoV-2 infection, considering COVID-19 as a valuable study model. By examining these parallels, we can enhance our knowledge and comprehension of PE. We wish to emphasize the potential for COVID-19-induced myocardial injury in pregnant women and its connection to the increased maternal mortality rate.

show abstract

“…Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 14 and nuclear erythroid-2 related factor 2 (Nrf2) 15 , which are responsible for maintaining the redox balance in cells and generating a response to an inflammation 16 . The SARS-CoV-2 virus enters host cells via the angiotensin-converting enzyme 2 (ACE2) receptor 17 , which decreases the expression of the angiotensin II type-2 receptor and the placental growth factor (PlGF), and increases the expression of the angiotensin II type-1 receptor and soluble fms-like tyrosine kinase-1 (sFlt-1) 18 , 19 . These processes can disrupt mitochondrial function and trigger the overproduction of ROS, including O 2 − , and RNS.…”

Section: Introductionmentioning

confidence: 99%

Significance of nitrosative stress and glycoxidation products in the diagnosis of COVID-19

Wolszczak-Biedrzycka,

Dorf,

Matowicka-Karna

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Nitrosative stress promotes protein glycoxidation, and both processes can occur during an infection with the SARS-CoV-2 virus. Therefore, the aim of this study was to assess selected nitrosative stress parameters and protein glycoxidation products in COVID-19 patients and convalescents relative to healthy subjects, including in reference to the severity of COVID-19 symptoms. The diagnostic utility of nitrosative stress and protein glycoxidation biomarkers was also evaluated in COVID-19 patients. The study involved 218 patients with COVID-19, 69 convalescents, and 48 healthy subjects. Nitrosative stress parameters (NO, S-nitrosothiols, nitrotyrosine) and protein glycoxidation products (tryptophan, kynurenine, N-formylkynurenine, dityrosine, AGEs) were measured in the blood plasma or serum with the use of colorimetric/fluorometric methods. The levels of NO (p = 0.0480), S-nitrosothiols (p = 0.0004), nitrotyrosine (p = 0.0175), kynurenine (p < 0.0001), N-formylkynurenine (p < 0.0001), dityrosine (p < 0.0001), and AGEs (p < 0.0001) were significantly higher, whereas tryptophan fluorescence was significantly (p < 0.0001) lower in COVID-19 patients than in the control group. Significant differences in the analyzed parameters were observed in different stages of COVID-19. In turn, the concentrations of kynurenine (p < 0.0001), N-formylkynurenine (p < 0.0001), dityrosine (p < 0.0001), and AGEs (p < 0.0001) were significantly higher, whereas tryptophan levels were significantly (p < 0.0001) lower in convalescents than in healthy controls. The ROC analysis revealed that protein glycoxidation products can be useful for diagnosing infections with the SARS-CoV-2 virus because they differentiate COVID-19 patients (KN: sensitivity—91.20%, specificity—92.00%; NFK: sensitivity—92.37%, specificity—92.00%; AGEs: sensitivity—99,02%, specificity—100%) and convalescents (KN: sensitivity—82.22%, specificity—84.00%; NFK: sensitivity—82,86%, specificity—86,00%; DT: sensitivity—100%, specificity—100%; AGE: sensitivity—100%, specificity—100%) from healthy subjects with high sensitivity and specificity. Nitrosative stress and protein glycoxidation are intensified both during and after an infection with the SARS-CoV-2 virus. The levels of redox biomarkers fluctuate in different stages of the disease. Circulating biomarkers of nitrosative stress/protein glycoxidation have potential diagnostic utility in both COVID-19 patients and convalescents.

show abstract

The sFlt-1/PlGF Ratio in Pregnant Patients Affected by COVID-19

Cited by 9 publications

References 40 publications

sFlT-1/PlGF ratio as a predictor of preeclampsia in COVID-19 pregnant patients

sFlT-1/PlGF ratio as a predictor of preeclampsia in COVID-19 pregnant patients

SARS-CoV-2 Infection and Preeclampsia—How an Infection Can Help Us to Know More about an Obstetric Condition

Significance of nitrosative stress and glycoxidation products in the diagnosis of COVID-19

Contact Info

Product

Resources

About